You can buy or sell CLVS and other stocks, options, ETFs, and crypto commission-free!
Clovis Oncology, Inc. Common Stock, also called Clovis Oncology, is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Read More Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
52 Week High
52 Week Low
Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
Clovis Oncology, Inc. CLVS incurred adjusted loss of $1.63 per share in the first quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of $1.80. However, it was wider than the year-ago loss of $1.38 per share. Net revenues, entirely from Clovis' only marketed drug, Rubraca, were approximately $33.1 million in the quarter, up 8.9% sequentially. The top line also beat the Zacks Consensus Estimate of $31.68 million. The company had recorded total revenues of $18.5 million, entirely from Rubra...
Yahoo FinanceMay 7
Clovis Oncology Announces First Quarter 2019 Operating Results
BOULDER, Colo.--(BUSINESS WIRE)-- $33.1M in Rubraca ® (rucaparib) global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at Fall 2019 medical meeting Clovis-sponsored combination studies of lucitanib with rucaparib and Bristol-Myers Squibb’s Opdivo expected to begin in mid...
Seeking AlphaMay 6
Clovis Oncology, Inc. Q1 2019 Earnings Preview
Clovis Oncology, Inc. (NASDAQ:CLVS) is scheduled to announce Q1 earnings results on Tuesday, May 7th, before market open. The consensus EPS Estimate is -$1.73 (-12.3% Y/Y) and the consensus Revenue Estimate is $32.1M (+73.3% Y/Y). Over the last 2 years, clvs has beaten EPS estimates 38% of the time and has beaten revenue estimates 50% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 3 upward revisions and 0 downward....
Expected Jul 31, Pre-Market